NO20075087L - Kombinasjoner, metoder og sammensetninger for behandling av cancer - Google Patents

Kombinasjoner, metoder og sammensetninger for behandling av cancer

Info

Publication number
NO20075087L
NO20075087L NO20075087A NO20075087A NO20075087L NO 20075087 L NO20075087 L NO 20075087L NO 20075087 A NO20075087 A NO 20075087A NO 20075087 A NO20075087 A NO 20075087A NO 20075087 L NO20075087 L NO 20075087L
Authority
NO
Norway
Prior art keywords
treatment
methods
cancer
compositions
combinations
Prior art date
Application number
NO20075087A
Other languages
English (en)
Norwegian (no)
Inventor
Francis Y F Lee
Roberto Weinmann
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20075087L publication Critical patent/NO20075087L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20075087A 2005-04-13 2007-10-09 Kombinasjoner, metoder og sammensetninger for behandling av cancer NO20075087L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
NO20075087L true NO20075087L (no) 2008-01-09

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075087A NO20075087L (no) 2005-04-13 2007-10-09 Kombinasjoner, metoder og sammensetninger for behandling av cancer

Country Status (12)

Country Link
US (2) US20060235006A1 (pl)
EP (1) EP1868435A4 (pl)
JP (1) JP2008536853A (pl)
KR (1) KR20080004495A (pl)
AU (1) AU2006236812A1 (pl)
BR (1) BRPI0608176A2 (pl)
CA (1) CA2604581A1 (pl)
EA (1) EA200702238A1 (pl)
MX (1) MX2007012537A (pl)
NO (1) NO20075087L (pl)
TW (1) TW200722091A (pl)
WO (1) WO2006113304A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3222619A1 (en) * 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
CN101155579B (zh) 2005-02-03 2012-10-31 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2610157A1 (en) * 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
MX2008012728A (es) * 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
CA2644841C (en) * 2006-04-07 2013-07-16 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2222166B9 (en) * 2007-12-10 2012-11-07 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
WO2011011027A1 (en) * 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
CN109464445A (zh) * 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
EP2370175A2 (en) * 2008-12-16 2011-10-05 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
AU2010302961A1 (en) * 2009-10-01 2012-04-19 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
EP3222619A1 (en) * 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
BR0209647A (pt) * 2001-05-16 2004-07-27 Novartis Ag Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
AR047530A1 (es) * 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
US20060235006A1 (en) 2006-10-19
AU2006236812A1 (en) 2006-10-26
JP2008536853A (ja) 2008-09-11
EP1868435A4 (en) 2009-04-01
WO2006113304A3 (en) 2007-08-02
MX2007012537A (es) 2007-12-10
TW200722091A (en) 2007-06-16
BRPI0608176A2 (pt) 2009-11-17
EA200702238A1 (ru) 2008-04-28
EP1868435A2 (en) 2007-12-26
WO2006113304A2 (en) 2006-10-26
KR20080004495A (ko) 2008-01-09
US20090054415A1 (en) 2009-02-26
CA2604581A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
NO20075087L (no) Kombinasjoner, metoder og sammensetninger for behandling av cancer
GEP20104927B (en) Formulations of a src/abl inhibitor
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
SV2002000287A (es) Uso de inhibidor de la quinasa dependiente de la ciclina para preparar una composicion farmaceutica util para tratar enfermedades neurodegenerativas
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
ATE423105T1 (de) Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
DK1585743T3 (da) 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
NO20062022L (no) 1-(kinolinamino)- og 1-(isokinolinamino)-substituerte pentan-2-oler, fremgangsmate for fremstilling av disse og anvendelse av den som antiinflammatoriske midler
BRPI0614481A2 (pt) composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5
SE0402284D0 (sv) New heterocyclic amides
UY29165A1 (es) Nuevo procedimiento y compuestos intermedios de preparación de derivados de n-(1-benzhidril-azetidin-3-il)-n-fenil-metilsulfonamida.
BRPI0510865A (pt) inibidores seletivos de butirilcolinesterase: composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application